随着美国食品药品监督管理局（FDA）批准首个CRISPR/Cas9基因编辑疗法，CASGEVY创造了历史。 - Suppr

Suppr

超能文献

CASGEVY Makes History as FDA Approves First CRISPR/Cas9 Genome Edited Therapy.

作者信息

Philippidis Alex

出版信息

Hum Gene Ther. 2024 Jan;35(1-2):1-4. doi: 10.1089/hum.2023.29263.bfs.

DOI:10.1089/hum.2023.29263.bfs

PMID:38231658

Abstract

摘要

相似文献

CASGEVY Makes History as FDA Approves First CRISPR/Cas9 Genome Edited Therapy.

Hum Gene Ther. 2024 Jan;35(1-2):1-4. doi: 10.1089/hum.2023.29263.bfs.

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.

Med Sci Monit. 2024 Mar 1;30:e944204. doi: 10.12659/MSM.944204.

Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease.

Ann Med Surg (Lond). 2024 May 15;86(8):4555-4559. doi: 10.1097/MS9.0000000000002146. eCollection 2024 Aug.

No apparent p53 activation in CRISPR-engineered gene-edited rabbits.

J Cell Mol Med. 2021 Nov;25(21):10313-10317. doi: 10.1111/jcmm.16960. Epub 2021 Oct 5.

Generation of Genome-Edited Mice by Cytoplasmic Injection of CRISPR-Cas9 RNA.

Methods Mol Biol. 2023;2637:75-86. doi: 10.1007/978-1-0716-3016-7_6.

Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.

Biomaterials. 2020 Mar;234:119711. doi: 10.1016/j.biomaterials.2019.119711. Epub 2020 Jan 10.

Harnessing heterologous and endogenous CRISPR-Cas machineries for efficient markerless genome editing in Clostridium.

Sci Rep. 2016 May 9;6:25666. doi: 10.1038/srep25666.

CRISPR/Cas9-Based Genome Editing of Transcription Factor Genes in Marchantia polymorpha.

Methods Mol Biol. 2018;1830:109-126. doi: 10.1007/978-1-4939-8657-6_7.

CRISPR-Cas9-Edited Site Sequencing (CRES-Seq): An Efficient and High-Throughput Method for the Selection of CRISPR-Cas9-Edited Clones.

Curr Protoc Mol Biol. 2018 Jan 16;121:31.14.1-31.14.11. doi: 10.1002/cpmb.53.

CRISPR/Cas9-mediated genome editing of Schistosoma mansoni acetylcholinesterase.

FASEB J. 2021 Jan;35(1):e21205. doi: 10.1096/fj.202001745RR.

引用本文的文献

The Era of Gene Therapy: The Advancement of Lentiviral Vectors and Their Pseudotyping.

Viruses. 2025 Jul 24;17(8):1036. doi: 10.3390/v17081036.

Viral and nonviral nanocarriers for CRISPR-based gene editing.

Nano Res. 2024 Oct;17(10):8904-8925. doi: 10.1007/s12274-024-6748-5. Epub 2024 Jun 20.

Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up.

Drug Saf. 2025 Aug 9. doi: 10.1007/s40264-025-01596-9.

CRISPR/Cas9 for achieving postintervention HIV control.

Curr Opin HIV AIDS. 2025 Sep 1;20(5):432-440. doi: 10.1097/COH.0000000000000963. Epub 2025 Jul 18.

Current perspectives on gene therapy and its involvement in curing genetic disorders.

Hum Genet. 2025 Jun 18. doi: 10.1007/s00439-025-02757-7.

Innovations in Drug Discovery for Sickle Cell Disease Targeting Oxidative Stress and NRF2 Activation-A Short Review.

Int J Mol Sci. 2025 Apr 28;26(9):4192. doi: 10.3390/ijms26094192.

Donor insertion into CX3CR1 allows epigenetic modulation of a constitutive promoter on hematopoietic stem cells and its activation upon myeloid differentiation.

Nucleic Acids Res. 2025 Apr 22;53(8). doi: 10.1093/nar/gkaf344.

From bench to bedside: the future of stable lentiviral packaging cell lines in gene therapy.

Gene Ther. 2025 Apr 26. doi: 10.1038/s41434-025-00537-6.

Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies.

Nat Commun. 2025 Apr 1;16(1):3103. doi: 10.1038/s41467-025-58371-8.

Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects.

Expert Rev Mol Med. 2025 Mar 31;27:e16. doi: 10.1017/erm.2025.10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验